Back to search

Article

Development of N-terminally modified variants of the CXCR4-antagonizing peptide EPI-X4 with increased plasma stability

2022-11-01

Abstract excerpt

EPI-X4 is a natural peptide antagonist of CXCR4, an established drug target in inflammatory diseases and cancer. Advanced derivatives of EPI-X4, such as EPI-X4 JM#21, have shown promising therapeutic effects in animal models of CXCR4-associated diseases but suffer from poor stability in blood. We here aimed to design and characterize EPI-X4 analogs that effectively antagonize CXCR4 while remaining stable in human...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
95aeba7f-12d9-5584-a80f-ae5f5e7df977
DOI
10.22541/au.166733107.78559129/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Development of N-terminally modified variants of the CXCR4-antagonizing peptide EPI-X4 with increased plasma stabilityDOI 10.22541/au.166733107.78559129/v1
Select a neighboring publication to make it the new centre.